Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.

Expression of CD3 and CD8 The refractory Bev group showed a trend toward an increased number of CD8+ T cells compared with the naïve Bev group (naïve Bev group, 14.9/5HPF; refractory Bev group, 20.8/5HPF; effective Bev group, 18.6/5HPF; naïve vs refractory Bev group, P = .06; naïve vs effective Bev group, P = .12) (Figure 3 A,B).

also in 53,322 other papers